Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application 2019-08-12 19:00
EnGeneIC Wins Innovation Award from Australian Financial Review 2019-08-09 12:49
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer 2019-08-08 20:30
111 Wins 2019 China Healthcare Industry Best Corporate Award 2019-08-08 08:00
CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park 2019-08-07 14:47
EDAN Announces Relocation and Expansion of Its US Operation Hub 2019-08-06 23:17
China Biologic Reports Financial Results for the Second Quarter of 2019 2019-08-06 04:30
New Drug for Diabetes-Induced Vision Loss TGA-Approved for Australian Patients 2019-08-05 20:00
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors 2019-08-01 20:06
111 to Announce Second Quarter 2019 Unaudited Financial Results on August 15, 2019 2019-08-01 20:00
New Texas Imaging Center Utilizing United Imaging Equipment, Demonstrating the Innovation of Cutting-Edge Portfolio in the U.S. 2019-08-01 20:00
Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal 2019-07-31 19:00
GC Pharma Reports Q2 2019 Results 2019-07-30 22:31
Alvotech and Cipla Gulf Enter Into a Partnership for the Commercialization of Key Biosimilar in Select Emerging Markets 2019-07-29 12:00
China Biologic Products to Report Second Quarter 2019 Financial Results 2019-07-27 04:30
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock 2019-07-25 04:05
NanoCellect Biomedical Expands Distribution to Australia and New Zealand 2019-07-24 21:57
111 Signs Strategic Cooperation with Harbin Pharmaceutical Group 2019-07-24 20:00
Shanghai Concord Medical Cancer Center has Accepted Medical Insurance Settlement from Patients from certain Yangtze River Delta Regions 2019-07-23 18:03
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML 2019-07-22 12:17
1 216 217 218 219 220 430